Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Zhuoxin Yu"'
Autor:
Xiufang Li, Zongling Liu, Haoming Wu, Zhuoxin Yu, Jiaorong Meng, Haiyun Zhao, Xingli Deng, Yizu Su, Baoshan Chen, Ru Li
Publikováno v:
Phytopathology Research, Vol 6, Iss 1, Pp 1-15 (2024)
Abstract Sugarcane (Saccharum spp.) is a major sucrose and bioenergy crop in the world. The fungal pathogen Sporisorium scitamineum causes sugarcane smut, a devastating disease that destroys stalks and reduces sugar content in sugarcane. This disease
Externí odkaz:
https://doaj.org/article/a17202c4f3714d4e8b314528235d5cbb
Publikováno v:
Journal of Fungi, Vol 10, Iss 9, p 631 (2024)
Sporisorium scitamineum is a biotrophic fungus responsible for inducing sugarcane smut disease that results in significant reductions in sugarcane yield. Resistance mechanisms against sugarcane smut can be categorized into structural, biochemical, an
Externí odkaz:
https://doaj.org/article/ce54f6d1f2a44659a27def8fc72eb097
Publikováno v:
IET Generation, Transmission & Distribution, Vol 17, Iss 5, Pp 1135-1147 (2023)
Abstract The battery swapping mode is a promising way for electric vehicles (EVs) to participate in power grid frequency regulation. However, the operation mechanism and the uncertainty management in the process still lack research. Aiming at this is
Externí odkaz:
https://doaj.org/article/3db01c867523438d91d10afa333c5c26
Publikováno v:
IET Generation, Transmission & Distribution. 17:1135-1147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bb3e72c9638fdbaed82e667b31831c4
https://doi.org/10.1049/gtd2.12722
https://doi.org/10.1049/gtd2.12722
Autor:
Raleigh E. Malik, Anita Y. M. Kwan, Juan P. Frias, David A. Cox, Joanna Van, Reema Mody, Enzo Bonora, Angelyn Bethel, Francisco J. Tinahones, Zhuoxin Yu
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD‐11 trial. Materials and Methods Patients were randomized to once‐weekly dulagl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6adb364371c8e0e6ecf010f8ccaeb0
https://doi.org/10.1111/dom.14465
https://doi.org/10.1111/dom.14465
Autor:
Matias Rodrigo Chacon, Hernan J. Cutuli, Sergio Bracarda, Marco Maruzzo, Maria Teresa Bourlon, Carmel Jacobs, Begoña Pérez-Valderrama, Ignacio Magri, Martin Richardet, Piotr Centkowski, Simon Yuen Fai Fu, Pablo Gurman, Srivani Konduri, Zhuoxin Yu, Heather Vezina, Saby George, Laurence Albiges
Publikováno v:
Journal of Clinical Oncology. 40:TPS4621-TPS4621
TPS4621 Background: Nivolumab (NIVO), a programmed death-1 immune checkpoint inhibitor, has demonstrated clinical efficacy across patients with different tumor types, including clear cell renal cell carcinoma (ccRCC), when administered via IV infusio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae5088958136f536be42cf3b170d4d04
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4621
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4621
Autor:
Zvonko Milicevic, E Heitmann, Enzo Bonora, Angelyn Bethel, J Frias, Zhuoxin Yu, Raleigh E. Malik, David A. Cox, LN Ruiz
Publikováno v:
Präzisionsmedizin – Eine Reise in die Zukunft der Diabetologie www.diabeteskongress.de.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::869c96467743b2d25da7a2d576905f9c
https://doi.org/10.1055/s-0041-1727332
https://doi.org/10.1055/s-0041-1727332
Autor:
Zhuoxin Yu, Luis Nevárez Ruiz, M. Angelyn Bethel, Raleigh E. Malik, Zvonko Milicevic, Enzo Bonora, Ying G. Li, Juan P. Frias, David A. Cox
Publikováno v:
Diabetes Care
OBJECTIVE To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS Patients were randomly assigned to once-weekly dulag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad7a41393f7cc0eed8d6c9ebabee323
https://pubmed.ncbi.nlm.nih.gov/33397768
https://pubmed.ncbi.nlm.nih.gov/33397768
Autor:
Zhuoxin Yu, Zvonko Milicevic, Enzo Bonora, Grace Li, Juan P. Frias, David A. Cox, Angelyn Bethel, Luis Nevárez Ruiz, Raleigh E. Malik
Publikováno v:
Diabetes. 69
Dulaglutide (DU) is approved at 2 doses (0.75 and 1.5 mg) for treatment of T2D. In this phase 3 study, once weekly DU 3 mg and 4.5 mg were compared to DU 1.5 mg for efficacy and safety through 52 weeks (wks) (primary endpoint at 36 wks) in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e639e06e188347046e7f6ad69039280
https://doi.org/10.2337/db20-357-or
https://doi.org/10.2337/db20-357-or
Autor:
Luis Nevárez Ruiz, Zvonko Milicevic, Zhuoxin Yu, Juan P. Frias, Ying Grace Li, David A. Cox, Brad Woodward
Publikováno v:
Journal of the Endocrine Society
Dulaglutide (DU) approved at doses of 0.75 and 1.5 mg once-weekly is an effective glucose lowering agent for treatment of type 2 diabetes (T2D). We hypothesized that higher investigational DU doses may provide further improvements in glucose control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6eb2512957573edadca3f3c48c14024
https://doi.org/10.1210/jendso/bvaa046.2057
https://doi.org/10.1210/jendso/bvaa046.2057